US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit

By Meghan Kelly · December 15, 2020, 5:46 PM EST

Mylan Pharmaceuticals has urged a Kansas federal judge to drop it from a suit alleging it inflated the price for the emergency allergy medication EpiPen, arguing the retail and online pharmacy...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

2:17-md-02785

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Featured Stories

What To Know: FDA Compounding Panel Weighs Peptides No Photo Available

Dan McKay

A panel advising the U.S. Food and Drug Administration will weigh in this week on a push to expand legal access to seven peptides that... (more story)

This Week's Healthcare Earnings: UnitedHealth, J&J, Elevance No Photo Available

Yeji Jesse Lee

Payors UnitedHealth and Elevance and pharma giant Johnson & Johnson all raised their 2026 guidance after positive second quarters. Law... (more story)

Wyeth's Patent Loss Has Attys Focusing On Dosage No Photo Available

Dani Kass

The Federal Circuit's holding that a Pfizer unit's cancer treatment patents are invalid highlights the risk of including dosages in pa... (more story)